Ofloxacin: therapeutic results in Chlamydia trachomatis urethritis.
Sexually transmitted Chlamydia trachomatis infection of the genito-urinary tract is becoming recognized as a disease which has reached a higher incidence than gonococcal infections, and caused severe and complicated infections in males and females even without major complaints. The MicroTrak test is used to demonstrate C. trachomatis by direct identification under the fluorescence microscope using fluorescein-labelled monoclonal antibodies. 20 patients (15 males, five females) with proven C. trachomatis urethritis were treated for five days with 2 X 200 mg ofloxacin. The initial cure rate was 90% (18 of 20 patients) with an additional 10% being cured after extended therapy over ten days. No side-effects occurred during ofloxacin therapy. Thus ofloxacin can be regarded as an effective and safe drug for the treatment of the genito-urinary infections caused by C. trachomatis.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002690:Chlamydia Infections / Q000188:drug therapy*; D002692:Chlamydia trachomatis; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin; D010078:Oxazines / Q000627:therapeutic use*; D012749:Sexually Transmitted Diseases / Q000188:drug therapy*; D014526:Urethritis / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D010078:Oxazines; D015242:Ofloxacin